Secukinumab is a monoclonal antibody that blocks interleukin-17A, a cytokine central to the inflammation of psoriasis and related conditions. Targeting it produces remarkably complete skin clearance - a substantial proportion of people reach almost clear skin. The same pathway has a different role in the gut, which is why one group of people should not take it, and that distinction is the most useful thing to understand about the class.
Follow the plan your specialist gave you. This guide contains no doses.
It can worsen bowel disease
Interleukin-17 helps maintain the gut's defence against bacteria and the integrity of the intestinal barrier. Blocking it can allow inflammation in the bowel rather than reducing it.
Trials of IL-17 inhibitors in Crohn's disease were stopped early because patients worsened, and new-onset or flaring inflammatory bowel disease has been reported during treatment for psoriasis.
Secukinumab is therefore avoided in Crohn's disease and ulcerative colitis, and used cautiously where there is a family history or suggestive symptoms.
Report persistent diarrhoea, blood in the stool, abdominal pain or unexplained weight loss.
This matters because psoriasis, psoriatic arthritis and inflammatory bowel disease frequently occur in the same person - and where both are present, a TNF inhibitor treats both. See adalimumab and etanercept, which does not work in Crohn's either.
What it treats
- Moderate to severe plaque psoriasis, where it is among the most effective treatments available
- Psoriatic arthritis
- Axial spondyloarthritis, including ankylosing spondylitis
- Hidradenitis suppurativa
NHS access is within defined criteria based on severity scores and previous treatments.
It works quickly for skin - improvement is often visible within a few weeks, faster than with methotrexate or ciclosporin. See methotrexate.
Thrush and other candida
Interleukin-17 is specifically important in defence against candida, so blocking it makes fungal infection of the mouth, throat, skin and genitals more common.
These are usually mild and respond to standard treatment, and they are rarely a reason to stop.
Report persistent or recurrent thrush - see nystatin, clotrimazole and fluconazole.
Screening before starting
Tuberculosis screening is required - history, chest X-ray and an interferon gamma release assay - along with hepatitis B and C serology.
The TB reactivation risk with IL-17 inhibitors appears lower than with TNF inhibitors, but screening is still done and latent TB treated.
See infection risk on immune-suppressing medicines.
Infection and vaccines
Upper respiratory infections are the commonest side effect, and serious infections occur less often than with some other biologics.
Seek medical advice promptly for fever, a cough that will not settle, or a wound that is not healing. Treatment is paused during a significant infection.
Live vaccines are avoided during treatment. Inactivated vaccines - influenza, pneumococcal, COVID and the non-live shingles vaccine - are recommended.
Carry your biologic alert card.
Injecting it
Secukinumab is given by subcutaneous injection - weekly loading doses, then monthly - using a pre-filled pen or syringe into the thigh or abdomen, rotating sites.
Most people self-inject after training.
Take it from the fridge and let it reach room temperature for around half an hour before injecting - cold solution stings considerably more, and this is the simplest way to reduce injection discomfort.
Store in the fridge, never frozen, and use a cool bag for travel - see medicines that need the fridge and flying with prescription medicines.
Used devices go in a sharps bin - see needles and sharps disposal.
No routine blood monitoring
Unlike methotrexate and ciclosporin, secukinumab does not require regular blood counts and liver tests.
For someone who has spent years attending for monitoring, that is a substantial practical difference - see dupilumab, which shares it.
Keep treating the skin
Emollients continue, and topical treatment is still used for residual patches - though usually far less of it.
See emollients and betamethasone.
Latex
The needle cover of some secukinumab pre-filled devices contains a latex derivative.
If you have a latex allergy, tell your team - alternative presentations exist, and this is the kind of detail that gets missed when a device changes. See allergy or side effect.
Other points
It has no significant drug interactions, which is unusual and useful.
It is long-term treatment rather than a course - psoriasis returns after stopping in most people.
If it loses effect after a period of good response, that is worth reporting; antibodies against the drug develop in a minority, and switching to a different biologic is the usual answer.
Ixekizumab and bimekizumab work on the same pathway, with the same bowel disease caution.
If this was useful, Upadacitinib: A Selective JAK Inhibitor is worth reading next, and Conditions collects the rest.